Share on Pinterest GLP-1 drugs may improve brain and heart health but could cause problems for the kidneys and pancreas, according to a new study. FreshSplash/Getty Images Researchers report that ...
GLP-1 drug users initially spend less on groceries, but that impact levels out over the course of a year, according to a new report. Frozen foods, fatty proteins and sugary beverages face big sales ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of ...
Share on Pinterest A new study compares the risks and benefits of using GLP-1 medications. Iuliia Burmistrova/Getty Images The use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists ...
A new study reports that GLP-1 medications may provide benefits to cognitive and behavioral health, including lowered addiction risk. Scientists also confirmed that the use of these medications ...
TUESDAY, Jan. 21, 2025 (HealthDay News) -- Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as substance abuse, psychosis, ...
Nobody could have predicted the vogue for GLP-1 drugs to promote weight loss. In the US alone, the number of patients starting GLP-1 treatments for nondiabetic purposes has increased by 700% since ...
Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders. HealthDay News — For people with diabetes, the use of glucagon ...
Add a description, image, and links to the nf-kb topic page so that developers can more easily learn about it.
Oprah Winfrey says taking a GLP-1 drug such as Ozempic and Wegovy has changed her entire perspective on “thin people.” A Type 2 diabetes medication that can also aid in weight loss ...
If you continue to have this issue please contact [email protected]. Previous studies suggest GLP-1 receptor agonists may benefit those with Parkinson’s disease. A phase 3 randomized ...